[ad_1]
Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA) are expected to capture the lion’s share of COVID-19 vaccine sales in 2021 and together will total $ 14.7 billion (£ 10.8 billion) in revenue over the next three years.
New data has shown that 2021 in particular “is set to become an important year for pharmaceutical companies leading the COVID-19 vaccine race, with significant revenue at stake,” research firm Finaria said.
The vaccine developed by Massachusetts biotech company Moderna is expected to generate more than $ 3.5 billion in revenue this year, $ 400 million more than the BioNTech-Pfizer vaccine.
This jab has been approved in the US, UK, EU, Canada and Israel. Data shows that its annual revenue is expected to remain around $ 2.9 billion over the next two years.
Last month, the UK became the first Western country to approve a COVID-19 vaccine when it cleared candidate Pfizer-BioNTech. The United States followed suit, and the vaccine also gained emergency approval in Canada and conditional approval in the European Union.
The vaccine is expected to generate more than $ 3.1 billion in sales in 2021. However, that figure is expected to drop to less than $ 1.4 billion in 2022 and continue to decline over the next several years. In 2023, sales of BionTech-Pfizer COVID-19 vaccines are expected to generate $ 914 million, almost 3.5 times lower than in 2021.
The downside of the BioNTech-Pfizer vaccine is its need for ultra-cold storage. Many countries do not have the logistics required.
Meanwhile, the largest number of doses ordered is that of the vaccine developed by AstraZeneca (AZN.L) and the University of Oxford.
READ MORE: Goldman Sachs: vaccine rollout could trigger exceptional rebound for UK
At the start of 2021, there were pre-purchase agreements for nearly three billion doses for the AstraZeneca / Oxford vaccine.
One of its biggest advantages is the ability to store at average refrigerator temperature.
Although still in phase 3 clinical trials and without approval, Novavax’s vaccine is the second highest by number of orders in the world, at nearly 1.3 billion.
Finaria said the BioNTech-Pfizer vaccine reached 816 million doses ordered last week. Gamaleya, Sanofi / GSK and Moderna followed with 727 million, 712 million and 441 million orders, respectively.
As of January 10, a total of 25.8 million doses of the COVID-19 vaccine had been administered worldwide, Finaria said.
Statistics show that China accounted for nearly a third of that number, with 9 million doses of the vaccine. The United States ranked second with more than 8 million doses administered last week.
The United Kingdom, Israel and the United Arab Emirates follow with 2 million, 1.8 million and 1 million doses respectively.
Earlier Tuesday, economists at Goldman Sachs (GS) said the successful rollout of COVID-19 vaccines could lead to a strong rebound in UK and US GDP from the second quarter.
The UK vaccinates an average of 140 people per minute against the coronavirus, Vaccine Deployment Minister Nadhim Zahawi said on Monday.
Britain is currently leading the vaccination race in Europe, having become the first country to endorse the Pfizer jab.
About 2.2 million people received the first dose of a COVID-19 vaccine between December 8, 2020 and January 10, 2021 in the UK, with mass vaccination sites also open on Monday.
Watch: Vaccine volunteers help with deployment
[ad_2]
Source link